Clinical Investigations: Acute Ischemic Heart DiseaseThe prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: The FRISC II invasive troponin T electrocardiogram substudy*,**,★
Section snippets
Patients
In the FRISC II trial, 2457 patients were randomized to an invasive or noninvasive regimen. The details of the design and the main results have been published.12 Inclusion criteria were symptoms of cardiac ischemia associated with either ST depression ≥0.1 mV or T wave inversion ≥0.1 mV in at least 1 lead or elevation of biochemical marker of myocardial damage.
In this study, only patients with plasma samples for central evaluation of the troponin T level and electrocardiographic results for
Electrocardiogram on admission and troponin T level at randomization
Admission electrocardiograms for evaluation regarding STT changes and plasma samples allowing troponin T level analysis were available in 2286 patients (93% of the total study population). The median time elapsed from start of chest pain to collection of blood samples was 39 hours (interquartile range, 27 to 54 hours). Around one third of patients had troponin T level elevation (ie, ≥0.03 μg/L) and ST depression, one third had troponin T level elevation only, and one third had no troponin T
Prognosis in the noninvasive group
An elevated troponin T level and ST depression in electrocardiographic results at entry have been associated with an elevated risk of future events.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 In this study, the worst prognosis was seen in patients with the combination of troponin T level ≥0.03 μg/L and ST depression, with a 22% rate of death or myocardial infarction and a 5.9% mortality rate at 12 months, both of which were more than twice as high as in the rest of the study population. Also, in the
Acknowledgements
We thank all patients who agreed to participate for their invaluable contribution and the research nurses, monitors, investigators, coordinators, core laboratories, endpoint committee, and data safety monitoring board for their dedicated work.
References (18)
- et al.
Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group
J Am Coll Cardiol
(1997) - et al.
Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management
Lancet
(1999) - et al.
The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia
J Am Coll Cardiol
(1997) - et al.
Four-year survival of patients with acute coronary syndromes without ST-segment elevation and prognostic significance of 0.5-mm ST-segment depression
Am J Cardiol
(1999) - et al.
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease
Lancet
(2000) - et al.
Coronary angiographic findings and troponin T in patients with unstable angina pectoris
Am J Cardiol
(2000) - et al.
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration
Lancet
(1994) - et al.
Diagnostic performance and prognostic value of serum troponin T in suspected acute myocardial infarction
Scand J Clin Lab Invest
(1993) - et al.
Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group
Circulation
(1996)
Cited by (0)
- *
Supported by and organized in collaboration with the Pharmacia & Upjohn Company. Project organization within the research group also supported by the Swedish Heart-Lung Foundation and Uppsala County Association Against Heart and Lung Diseases.
- **
Reprint requests: Erik Diderholm, MD, Department of Cardiology, Cardiothoracic Center, University Hospital, S-751 85 Uppsala, Sweden.
- ★
E-mail: [email protected]